Adverse Reactions to Intravenous Immunoglobulins - Our Experience
DOI:
https://doi.org/10.3889/oamjms.2018.513Keywords:
Intravenous immunoglobulins, adverse reactionsAbstract
BACKGROUND: Adverse reactions to intravenous immunoglobulins (IVIG) are divided by organ system involved, or by timing of onset–immediate which occur during infusion usually rate-related, true IgE-mediated anaphylaxis and delayed reaction which occur hours to days after the infusion.
AIM: To describe the adverse events of patients given IVIG infusions.
METHODS: Total number of patients receiving IVIG was 41 with 25 males (60.97%) and 16 females (39.02%), age 2 months-35 years. A total number of infusions was 1350.
RESULTS: Total number of adverse reactions 15, 14 patients with immediate-type and 1 with delayed type. Total percentage of adverse reactions in a given sample was 1.1% of all IVIG infusions. Fever was the most common immediate type of reaction occurring in 11 patients (78.57%) followed by acrocyanosis 10 patients (71.42%), skin rash 9 patients (64.28%) and headache 8 patients (57.14). Delayed-type of reactions (like fever, headache and vomiting) was present in one patient. Majority of the adverse effects occurred at the infusion rate higher than 1, 5 ml/kg/hour, which is still within recommended speed.
CONCLUSION: About 1.1% of IVG infusions where with adverse events. Most common manifestations where: fever, acrocyanosis, skin rash and headache, which occurred 1-6 hours from the beginning of the infusion. The occurrence of adverse reactions to IVIG was related to the infusion rates in a fashion that faster infusion rate gives more reactions. Adverse reactions were managed by reduction of the infusion rate and administration of medications such as paracetamol, antihistamines and steroids.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Provan D, Nokes TJ, Agrawal S. IVIG Guideline Development Group of the IVIg Expert Working Group Clinical Guidelines for Immunoglobulin Use. 2008.
Kareva L. Intravenous immunoglobulin therapy in medical praxis. Journal of IMAB: Annual Proceeding (Scientific Papers). 2016; 22(4):1403-6. https://doi.org/10.5272/jimab.2016224.1403
Ballow M. The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. J Allergy Clin Immunol. 2011; 127:315–323. https://doi.org/10.1016/j.jaci.2010.10.030 PMid:21185071
Singh-Grewal D, Kemp A, Wong M. A prospective study of the immediate and delayed adverse events following intravenous immunoglobulin infusions.Arch Dis Child. 2006; 91:651–654. https://doi.org/10.1136/adc.2005.078733 PMid:16638785 PMCid:PMC2083046
Purisima BC, Garcia RD, Leus A. A retrospective study on the efficacy of Gammagard S/D IVIG versus Vizcarra IVIG in the treatment of Kawasaki disease in Makati Medical Center from 1998-2003. Philippine J Pediatr. 2009; 57:11–16.
Lemm G. Composition and properties of IVIg preparations that affect tolerability and therapeutic efficacy. Neurology. 2002; 59:S28–S32. https://doi.org/10.1212/WNL.59.12_suppl_6.S28 PMid:12499468
Dashti-Khavidaki S, Aghamohammadi A, Farshadi F, Movahedi M, Parvaneh N, Pouladi N, Moazzami K, Cheraghi T, Mahdaviani SA, Saghafi S, Heydari G, Abdollahzade S, Rezaei N. Adverse reactions of prophylactic intravenous immunoglobulin; a 13-year experience with 3004 infusions in Iranian patients with primary immunodeficiency diseases. J Investig Allergol Clin Immunol. 2009; 19:139–145. PMid:19476018
Kaba S, Keskindemirci G, Aydogmus C, Siraneci R, Erol FC. Immediate adverse reactions to intravenous immunoglobulin in children: a single center experience. European annals of allergy and clinical immunology. 2017; 49(1):11-4. PMid:28120600
Charhon N, Bonnet A, Schmitt Z, Charpiat B. A case of circulatory collapse during intravenous immunoglobulin therapy: A manageable adverse effect!. Anaesthesia, critical care & pain medicine. 2015; 34(2):113. https://doi.org/10.1016/j.accpm.2014.08.004 PMid:25858620
Bichuetti-Silva DC, Furlan FP, Nobre FA, Pereira CT, Gonçalves TR, Gouveia-Pereira M, Rota R, Tavares L, Mazzucchelli JT, Costa-Carvalho BT. Immediate infusion-related adverse reactions to intravenous immunoglobulin in a prospective cohort of 1765 infusions. International immunopharmacology. 2014; 23(2):442-6. https://doi.org/10.1016/j.intimp.2014.09.015 PMid:25257732
RodrÃguez-Mireles KA, Galguera-Sauceda A, Gaspar-López A, López-Rocha EG, Campos-Romero F, del Rivero-Hernández L, Amaya-MejÃa A, Galindo-Pacheco L, O'Farril-Romanillos P, Segura-Méndez NH. Adverse effects with ambulatory intravenous immunoglobulin administration in adult patients with common variable immunodeficiency. Revista Alergia México. 2014; 61(3):131-40. PMid:25177848
Palabrica FR, Kwong SL, Padua FR. Adverse events of intravenous immunoglobulin infusions: a ten-year retrospective study. Asia Pacific Allergy. 2013; 3(4):249-56. https://doi.org/10.5415/apallergy.2013.3.4.249 PMid:24260730 PMCid:PMC3826603
Singh-Grewal D, Kemp A, Wong M. A prospective study of the immediate and delayed adverse events following intravenous immunoglobulin infusions. Archives of disease in childhood. 2006; 91(8):651-4. https://doi.org/10.1136/adc.2005.078733 PMid:16638785 PMCid:PMC2083046
Hefer D, Jaloudi M. Thromboembolic events as an emerging adverse effect during high-dose intravenous immunoglobulin therapy in elderly patients: a case report and discussion of the relevant literature. Annals of hematology. 2004; 83(10):661-5. https://doi.org/10.1007/s00277-004-0895-2 PMid:15309520
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2018 Lidija Kareva, Kristina Mironska, Katerina Stavric, Arjeta Hasani
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
